Kaposi's sarcoma (KS) is a form of skin cancer that can involve internal organs. It is often found in patients with acquired immunodeficiency syndrome (AIDS) and can be fatal. Kaposi's sarcoma produces pink, purple or brown tumors on the skin, mucous membranes or internal organs. Treatment goals for KS are simple: to reduce the severity of the symptoms, shrink tumors and prevent disease progression. Unfortunately, there is no single best treatment-plan that can achieve all these goals. With widespread KS lesions over the body surface or evidence of spreading to other parts of the body, the physicians need to treat the patients with systemic chemotherapy. A new class of drugs, called liposomal anthracyclines, appears to produce good results with fewer toxic side effects than more conventional cytotoxic drugs. One of these drugs, pegylated liposomal doxorubicin (PLD) has become the treatment of choice. This article summarizes all the studies with PLD in systemic Kaposi's sarcoma.
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review / DI TROLIO, R; DI LORENZO, G; Delfino, Mario; DE PLACIDO, Sabino. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - STAMPA. - 19 (2):(2006), pp. 253-256.
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review
DELFINO, MARIO;DE PLACIDO, SABINO
2006
Abstract
Kaposi's sarcoma (KS) is a form of skin cancer that can involve internal organs. It is often found in patients with acquired immunodeficiency syndrome (AIDS) and can be fatal. Kaposi's sarcoma produces pink, purple or brown tumors on the skin, mucous membranes or internal organs. Treatment goals for KS are simple: to reduce the severity of the symptoms, shrink tumors and prevent disease progression. Unfortunately, there is no single best treatment-plan that can achieve all these goals. With widespread KS lesions over the body surface or evidence of spreading to other parts of the body, the physicians need to treat the patients with systemic chemotherapy. A new class of drugs, called liposomal anthracyclines, appears to produce good results with fewer toxic side effects than more conventional cytotoxic drugs. One of these drugs, pegylated liposomal doxorubicin (PLD) has become the treatment of choice. This article summarizes all the studies with PLD in systemic Kaposi's sarcoma.File | Dimensione | Formato | |
---|---|---|---|
role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma a systematic review.docx
non disponibili
Tipologia:
Abstract
Licenza:
Accesso privato/ristretto
Dimensione
11.28 kB
Formato
Microsoft Word XML
|
11.28 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
role of pegylated liposomal doxorubicin in Kaposi.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
6.31 MB
Formato
Adobe PDF
|
6.31 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.